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Abstract: Atherosclerosis and nonalcoholic fatty liver disease (NAFLD) are frequent causes of death
in the Western countries. Recently, it has been shown that autophagy dysfunction plays an important
role in the pathogenesis of both atherosclerosis and NAFLD; thus, activators of autophagy might
be useful for novel therapeutic interventions. Trehalose—a naturally occuring disaccharide present
in plants, bacteria, fungi, insects, and certain types of shrimps—is a known inducer of autophagy.
However, according to the literature, its anti-atherosclerotic and anti-steatotic potential seem to
depend on the experimental setting. The aim of our study was to comprehensively describe the
influence of a prolonged treatment with orally administered trehalose on the development of
atherosclerotic lesions and hepatic steatosis in apolipoprotein E knockout (apoE−/−) mice in an
experimental set up reflecting both moderate and severe proatherogenic conditions: male apoE−/−
mice on a chow diet (CD) and female apoE−/− mice fed with a high-fat diet (HFD). We found
that exogenous trehalose inhibited atherosclerosis and attenuated hepatic steatosis in apoE−/−
mice. Such effects of trehalose were not associated with changes of plasma cholesterol, low-density
lipoproteins (LDL), or high-density lipoproteins (HDL). Moreover, the anti-steatotic action of trehalose
in the liver was associated with the induction of autophagy. The exact molecular mechanisms of
both the anti-atherosclerotic action of trehalose and its inhibitory effect on liver steatosis require
further clarification.
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1. Introduction
Atherosclerosis and nonalcoholic fatty liver disease (NAFLD) are currently a worldwide public
health problem and among the frequent causes of death in the Western countries [1]. Atherosclerosis
is a complex inflammatory disease of the arterial wall, frequently associated with dyslipidemia,
characterized by endothelial activation, an accumulation of oxidized low-density lipoproteins,
subsequent migration of monocytes and other inflammatory cells to the subendothelial space, and their
excessive apoptosis/necrosis. Such processes progressively lead to the formation of atherosclerotic
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lesions with lipid-rich necrotic cores and rupture-prone fibrous caps [2,3]. A growing body of evidence
indicates that NAFLD is a key independent risk factor for atherosclerosis development [4]. Worldwide,
this complex common liver disorder is manifested by triglyceride accumulation in the cytoplasm of
hepatocytes and encompasses a wide spectrum of pathological conditions ranging from simple hepatic
steatosis to steatosis with inflammatory response, nonalcoholic steatohepatitis (NASH), cirrhosis and
fibrosis, and finally hepatocarcinoma [5].
Recently, it has been shown that autophagy dysfunction plays an important role in the
pathogenesis of both atherosclerosis and NAFLD [6,7]. Autophagy is an evolutionarily conserved
and self-protecting catabolic process of degradation of damaged organelles and misfolded proteins.
It uses many molecular pathways (in general, mammalian target of rapamycin (mTOR)-dependent
and/or mTOR-independent—for review, see reference [8]), contributes to the inhibition of apoptosis
and inflammation and the promotion of cholesterol efflux and efferocytosis (non-inflammatory cell
death and removal) in atherosclerotic lesions, as well as to the reduction of triglyceride levels in
hepatocytes [9,10]. Thus, activators of autophagy might be useful for therapeutic interventions in
atherosclerosis and NAFLD. Trehalose—a non-reducing, naturally occurring disaccharide, which
consists of two glucose units linked in an α,α-1,1-glycosidic linkage—is one of the known inducers
of autophagy [11]. It is widely distributed in the biological world, being common in plants, bacteria,
fungi, insects, and certain types of shrimps, where it serves as a protectant against environmental
stresses, such as cold, heat, oxidation, and dehydration [12,13]. Interestingly, trehalose is also a
popular stabilizer, sweetener, and humectant used in confectionery, beverages, bakery goods, rice,
and frozen food, as it has a lower sweetening intensity than sucrose and decreases the freezing point
of food [14]. The dietary intakes of trehalose are 5.7–9.7 g/day, as estimated for the populations
of the USA and Australia, and could reach 19 g occasionally (according to WHO Food Additives
Series 46: Trehalose). Noteworthy, despite the presence of trehalose-degrading enzyme (trehalase)
in the mammalian small intestine, orally administered trehalose has been proved to exert significant
biological effects in mouse models of obesity, fructose-induced lipid steatosis, muscular dystrophy,
and Huntington’s disease [15–18]). Surprisingly, so far, in animal models of atherosclerosis (high-fat
diet-fed apolipoprotein E knockout mice and high-cholesterol-fed rabbits), the action of trehalose
was observed only when administered parenterally [19,20]. Thus, the anti-atherosclerotic action of
trehalose seems to be critically dependent on the severity of the model and the experimental setting.
The apoE−/− mice are a widely utilized animal model of atherosclerosis, since they spontaneously
develop arterial lesions, dyslipidemia, and hypercholesterolemia, as well as changes in the liver
resembling mild hepatic steatosis [21,22]. The apoE−/− mice are considered a versatile model to
study the variability of the anti-atherosclerotic action of a given substance, as the development of
atherosclerotic plaques and hepatic steatosis in these animals varies depending on age, sex, and diet
and is the least severe in male mice on a chow diet and the most severe in female mice on a high-fat
diet [23–25].
Thus, the aim of our study was to comprehensively describe the influence of a 16-week treatment
with orally administered trehalose on the progression of atherosclerotic lesions and hepatic steatosis
in apoE−/− mice in an experimental set-up reflecting both moderate and severe proatherogenic
conditions: in male apoE−/− mice on a chow diet (CD) and female apoE−/− mice fed with a high-fat
diet (HFD) to determine whether oral administration of this disaccharide and under what conditions
might affect atherosclerosis and hepatic steatosis.
2. Results
2.1. The Influence of Trehalose on Atherosclerosis
The experimental design of our study is presented in Figure 1. There were no trehalose
treatment-related signs of toxicity in apoE−/− mice. As compared to untreated animals, treatment
with trehalose did not change the daily water or food intake in apoE−/− mice and did not influence
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the body weight of animals on a CD (32.2 ± 1.7 g vs. 32.1 ± 2.8 g) and an HFD (26.6 ± 1.2 g vs. 25.7
± 1.8 g). Trehalose caused a significant decrease of atherosclerotic lesions by almost 40% in the aorta
of apoE−/− mice fed a CD as measured by the en face method (11.5 ± 0.9% vs 15.8 ± 1.2%; p < 0.05)
(Figure 2A,B,C) and atherosclerosis evaluation at the aortic sinus (40118 ± 3904 µm2 vs 71492 ± 10703
µm2; p < 0.05) (Figure 2D,E,F). Moreover, trehalose treatment significantly increased the macrophage
content as evidenced by CD68 staining (43.7% ± 1.7% vs 29.3% ± 2%; p < 0.05) (Figure 3A,B,C) and
decreased the necrotic core as measured by the hematoxylin–eosin (HE) method (6.4% ± 0.4% vs 8.1%
± 0.4%; p < 0.05) (Figure 4G,H,I) in atherosclerotic plaques of apoE−/− mice on a CD. However, it
did not change the non-specific activity of gelatinases (mostly matrix metalloproteinases: MMP-2
and MMP-9) and the total collagen content as measured by in situ zymography (23.4% ± 2.66% vs
22.7% ± 0,9%; p > 0.05) and picro-sirius red staining (152993 ± 4490 µm2 vs 230862± 16329 µm2;
p = 0.059), respectively (Figure 4D,E,F). On the contrary, trehalose influenced neither the progression
of atherosclerosis (“cross section”: 271325.4 ± 7225.5 µm2 vs 275830.8 ± 12676.9 µm2; p > 0.05)
(Figure 2G,H,I) nor the content of macrophages (CD68 staining: 45.25% ± 1.7% vs 45.52% ± 3.4%;
p < 0.05) (Figure 3D,E,F) in apoE−/− mice fed an HFD. Real-time PCR experiments did not reveal any
significant changes of expression of genes related to autophagy (LC3B, ATG5, Beclin) in the aorta of
apoE−/− mice on CD or HFD upon trehalose administration (Figure 5A,B).
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Figure 2. Atherosclerotic lesions in trehalose-treated apoE-/- mice. Sudan IV-stained representative 
aortas in apoE−/− mice on a CD (A) and trehalose-treated apoE-/- mice on a CD (B). Representative 
micrographs showing oil-red O-stained atherosclerotic lesions measured by the atherosclerosis 
evaluation at the aortic sinus in the aorta of apoE−/− mice on a CD (D), trehalose-treated apoE−/− mice 
on a CD (E), apoE−/− mice on an HFD (G), and trehalose-treated apoE−/− mice on an HFD (H). 
Quantitative analysis of atherosclerotic lesions areas in apoE−/− mice and trehalose-treated apoE−/− 
mice on a CD or an HFD measured by the en face (C) or cross section methods (F,I) (mean ± SEM; * p 
< 0.05 as compared to apoE−/− mice on a CD; n = 7–11 per group). Scale bars = 500 μm. 
Figure 2. Atherosclerotic lesions in trehalose-treated apoE−/− mice. Sudan IV-stained representative
aortas in apoE−/− mice on a CD (A) and trehalose-treated apoE−/− mice on a CD (B). Representative
micrographs showing oil-red O-stained atherosclerotic lesions measured by the atherosclerosis
evaluation at the aortic sinus in the aorta of apoE−/− mice on a CD (D), trehalose-treated apoE−/−
mice on a CD (E), apoE−/− mice on an HFD (G), and trehalose-treated apoE−/− mice on an HFD (H).
Quantitative analysis of atherosclerotic lesions areas in apoE−/− mice and trehalose-treated apoE−/−
mice on a CD or an HFD measu by th en face (C) r cross sec i n methods (F,I) (mean ± SEM;
* p < 0.05 as compared t oE /− mice on a CD; n = 7–11 er group). Scale bars = 500 µm.
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Figure 3. Macrophage infiltrated in the atherosclerotic lesion of trehalose-treated apoE−/− mice.
Immunohistochemical staining of aortic roots showing CD68-positive macrophages (A,B,D,E) in
apoE−/− mice on a CD (A), trehalose-treated apoE−/− mice on a CD (B), apoE−/− mice on an HFD
(D), and trehalose-tr at d apoE−/− mice on an HFD (E). Quantitative analysis of atherosclerotic lesions
areas occupied by CD68-positive macrophages in E /− mice and trehalose-treated apoE−/− mice
on a CD and an HFD (C,F) (mean ± SEM; * p < 0.05 as compared to apoE−/− mice on a CD; n = 7–11
per group). Scale bars = 500 µm.
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Figure 4. Content of metalloproteinases, collagen and necrotic core in the atherosclerotic lesion
of trehalose-treated apoE−/− mice. I unohistochemic l staining showing non-specific activity
of gelatinases (mostly MMP-2 and M P-9) (A,B), total collagen (D,E) and necrotic core (G,H) in
atherosclerotic lesions of apoE−/− mice on a CD and trehalose-treated apoE−/− mice on a CD.
Quantitative analysis of atherosclerotic lesions areas occupied by non-specific activity of gelatinases
(mostly MMP-2 and MMP-9), total collagen, and necrotic core in apoE−/− ice and trehalose-treated
apoE−/− mice on a CD (C,F,I) (mean ± SEM; * p < 0.05 as compared to apoE−/− mice on a CD;
n = 7–11 per group). Scale bars = 500 µm.
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Figure 5. Influence of trehalose on autophagy in the aorta and liver of apoE−/− mice. Expression
level of genes related to autophagy: ATG5, Beclin-1, and LC3B in the aorta of apoE−/− mice and
trehalose-treated apoE−/− mice n a CD (A) and on an HFD (B) and in the liver of apoE−/− mice a d
trehalos -treat d apoE−/− mice on na HFD (C) (me ± SEM; = 4–5 per group).
2.2. The Influence of Trehalose on Hepatic Steatosis
The HE staining did not reveal major disturbances of the liver structure in both untreated
and trehalose-treated apoE−/− mice on a CD. Portal spaces were not enlarged and did not present
inflammatory infiltrates; only some hepatocytes had signs of granulation in the cytoplasm (Figure 6A,B).
On the contrary, the cytoplasm of hepatocytes in the liver of apoE−/− mice on n HFD had a granular
structure with signs of macrovesicular steatosis in about 30% of hepatocytes present in all three lobular
zones. The lobular structure of the liver was still preserved, and the portal spaces were minimally
enlarged and devoid of inflammatory infiltrates (Figure 6C). The treatment with trehalose caused a
reduction of macrovesicular steatosis, evident in about 7% of hepatocytes, mostly in the first zone
(Figure 6D,E). Moreover, trehalose administration resulted in a significant decrease of triglycerides
level by about 35% in the liver of apoE−/− mice on an HFD (Figure 6F). In addition, trehalose
treatment significantly decreased plasma alanine aminotransferase (ALT) level in apoE−/− mice on
an HFD (Figure 6G). Trehalose did not change the plasma levels of total cholesterol, low-density
lipoproteins (LDL), and high-density lipoproteins (HDL) in apoE−/− mice on a CD and an HFD
(Table 1). Importantly, the treatment with trehalose resulted in a significant decrease of plasma
triglycerides (TG) level only in apoE−/− mice on an HFD (Table 1).
Int. J. Mol. Sci. 2019, 20, 1552 8 of 16
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 16 
 
Group Total Cholesterol [mmol/L] HDL [mmol/L] LDL [mmol/L] TG [mmol/L] 
apoE−/− (CD) 13.4 ± 0.6 3.72 ± 0.95 8.24 ± 0.84 1.36 ± 0.22 
apoE−/− (CD) + trehalose 12.0 ± 3.20 3.58 ± 0.30 7.4 ± 0.88 1.48 ± 0.57 
apoE−/− (HFD) 27.24 ± 4.49 3.93 ± 0.83 22.51 ± 4.10 1.03 ± 0.22 
apoE−/− (HFD) + trehalose 25.25 ± 4.77 5.06 ± 0.50 19.90 ± 4.49 0.67 ± 0.12 * 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Influence of trehalose on hepatic steatosis in apoE-/- mice. Representative images of the livers 
of apoE−/− mice on a CD (A), trehalose-treated apoE−/− mice on a CD (B), apoE−/− mice on an HFD (D), 
and trehalose-treated apoE−/− mice on an HFD (E). The images show hematoxylin and eosin staining 
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Figure 6. Influence of trehalose on hepatic steatosis in apoE−/− mice. Representative images of the
livers of apoE−/− mice on a CD (A), trehalose-treated apoE−/− mice on a CD (B), apoE−/− mice on an
HFD (D), and trehalose-treated apoE−/− mice on an HFD (E). The images show hematoxylin and eosin
staining (A,B,D,E) and qu ntitative analysis of macroves cular steatosis (C), as well as TG content in
the liver (F) and plasma alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) levels in
apoE−/− mice and trehalose-treated apoE−/− mice on an HFD (G). Magnification 40x (mean ± SEM;
* p < 0.05 as compared to apoE−/− mice on a HFD; n = 3 or n = 7 per group). Scale bars = 50 µm.
Table 1. Plasma levels of total cholesterol, high-density lipoproteins (HDL), low-density lipoproteins
(LDL), and triglycerides (TG), presented as mean ± SD; * p < 0.05 as compared to the apoE−/− (HFD)
group; n = 4 per group.
Group Total Cholesterol [mmol/L] HDL [mmol/L] LDL [mmol/L] TG [mmol/L]
apoE−/− (CD) 13.4 ± 0.6 3.72 ± 0.95 8.24 ± 0.84 1.36 ± 0.22
apoE−/− (CD) + trehalose 12.0 ± 3.20 3.58 ± 0.30 7.4 ± 0.88 1.48 ± 0.57
apoE−/− (HFD) 27.24 ± 4.49 3.93 ± 0.83 22.51 ± 4.10 1.03 ± 0.22
apoE−/− (HFD) + trehalose 25.25 ± 4.77 5.06 ± 0.50 19.90 ± 4.49 0.67 ± 0.12 *
2.3. The Influence of Trehalose on Autophagy in The Liver
To investigate the molecular mechanisms responsible for the reduction of hepatic steatosis upon
trehalose treatment in the liver of apoE−/− mice on an HFD, we performed immunoblotting and
real-time PCR of key factors related to autophagy: Beclin-1, microtubule-associated proteins 1A/1B
light-chain 3B (LC3), and autophagy-related protein 7 (APG7). As compared to the untreated mice,
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the administration of trehalose resulted in a significant increase in the protein expression of Beclin-1,
LC3, LC3-II, and APG7 in the liver of apoE−/− mice on an HFD (Figure 7). However, real-time PCR
experiments did not reveal any significant change of expression of genes related to autophagy (LC3B,
ATG5, Beclin) in the liver of apoE−/− mice on an HFD upon trehalose administration (Figure 5C).
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Figure 7. Influence of trehalose on autophagy in the liver of apoE−/− mice. Expression level of APG7,
Beclin-1, LC3, LC3-II, and β-actin in the liver of apoE−/− mice and trehalose-treated apoE−/− mice on
an HFD (mean ± SEM; * p < 0.05 as compared to apoE−/− mice on an HFD; n = 4 per group).
3. Discussion
Several lines of evidence indicate that the impairment of autophagy contributes to the
pathogenesis of atherosclerosis and fatty liver disease and the pharmacological modulation of
autophagy could protect against the progression of these disorders [6,7]. In the present work, we have
shown that a known autophagy inducer—trehalose—given orally for a 16-week period and without
any visible adverse effects, inhibited atherosclerosis and attenuated hepatic steatosis in apoE−/− mice
fed with a chow and a high-fat diet, respectively. Noteworthy, such actions of trehalose were not
associated with changes of plasma cholesterol, LDL, or HDL.
Int. J. Mol. Sci. 2019, 20, 1552 10 of 16
3.1. The Influence of Trehalose on Atherosclerosis
In our hands, in the experimental layout corresponding to a gentle model of atherosclerosis,
i.e., in a CD-fed male apoE−/− mice, trehalose caused a 40% reduction of atherosclerotic plaques.
Interestingly, this was accompanied by an increased content of macrophages and decreased necrotic
cores in atherosclerotic lesions of apoE−/−mice. Recently, it has been shown that a macrophage-specific
dysfunction of autophagy is a hallmark of atherosclerotic lesions and contributes to atherogenesis
by the increased accumulation of protein aggregates, defective efferocytosis, and impaired lipid
degradation. Moreover, it has been shown that the stimulation of the macrophage autophagy-lysosomal
system through pharmacological or genetic interventions could be atheroprotective [9,19,26]. Although
the increased content of macrophages in atherosclerotic lesions may seem contradictory to the
anti-atherosclerotic action of trehalose, it could, in theory, reflect autophagy-related inhibition of
macrophage apoptosis and/or necrosis and enhanced macrophage autophagy-lysosomal biogenesis,
as the same effect was observed in atherosclerotic plaques upon treatment with rapamycin, an
mTOR pathway-dependent activator of autophagy [27]. Which macrophage phenotype (M1/M2)
predominates and whether, in terms of inflammatory reaction, trehalose may increase the number of
truly “silent” macrophages in the plaques require, however, further studies. In contrast to apoE−/−
mice on a chow diet, administration of trehalose to female apoE−/−mice fed with a high-fat diet did not
influence either the progression of atherosclerosis or the content of macrophages in the atherosclerotic
plaques. Interestingly, Sergin et al. showed that combined trehalose administration (i.p., 2 g/kg three
times per week and orally, 3% in drinking water) reduced the atherosclerotic lesions in apoE−/− mice
fed an HFD [19]. However, they concluded that the intraperitoneal administration of trehalose was
responsible for this effect, as the oral treatment alone did not decrease the atherosclerotic lesions in
apoE−/− mice on an HFD. Thus, our results are in keeping with their data. The question arises why
the anti-atherosclerotic effect of oral trehalose was attenuated on an HFD. One could speculate about
the reduction of trehalose absorption from the gastrointestinal (GI) tract caused by the HFD itself or
changes in the main GI trehalose metabolic pathways affecting trehalase levels or the bacterial flora [8].
However, the significant effect of trehalose treatment on liver steatosis in animals fed with an HFD
denies this hypothesis. Taking into account the presence of the enzyme trehalase in the intestinal
mucosa, which rapidly hydrolyses trehalose, the concentration of trehalose within the aortic wall could
be too low to inhibit atherogenesis in such an aggressive model as female apoE−/− mice on an HFD.
3.2. The Influence of Trehalose on Hepatic Steatosis
The liver structure of apoE−/− mice on a CD did not reveal significant disturbances; some
hepatocytes had signs of granulation of the cytoplasm. The treatment with trehalose did not change
the appearance of the liver of apoE−/− mice on a CD. On the contrary, the cytoplasm of hepatocytes in
the liver of apoE−/− mice on an HFD had a granular structure with signs of macrovesicular steatosis
in about 30% of cells. Importantly, the treatment with trehalose caused a reduction of steatosis, which
was evident in about 7% of hepatocytes. Such an effect was accompanied by a significant decrease of
triglyceride levels in the liver and plasma. Moreover, trehalose seemed to exert a hepatoprotective
effect, as it significantly diminished plasma ALT level in apoE−/− mice on an HFD.
The mechanism of trehalose action in the attenuation of hepatic steatosis in apoE−/− mice on
an HFD seems to be at least partially related to autophagy induction, as evidenced by the significant
increase in key proteins related to autophagy in the liver: LC3, Beclin-1, and APG7. In keeping with
our results, DeBosch et al. showed that trehalose administration reduced high-fructose diet-induced
hepatic steatosis in wild-type C57BL/6J mice through the inhibition of glucose transport via the
activation of AMP-activated protein kinase (AMPK)-dependent autophagy [15,28]. In addition, it
was observed that trehalose supplementation can have also other advantageous effects in metabolic
diseases: it mitigated insulin resistance, suppressed mesenteric adipocyte hypertrophy, increased the
plasma level of adiponectin in obese mice, and reduced hepatic endoplasmic reticulum stress in old
mice [16,29–31]. Thus, it is tempting to speculate that this disaccharide provides potentially a novel
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therapeutic approach to the treatment/prevention of fatty liver diseases and metabolic syndrome.
However, the exact mechanisms of the beneficial actions of trehalose require further studies. The
potential mechanisms of action of trehalose in atherosclerosis and hepatic steatosis are depicted in
Figure 8.
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3.3. Conc usions, Limitations of The Study, and Future Directions
We have found that trehalose, given orally for a 16-week period, was able to inhibit atherosclerosis
only in the less aggressive model examined (CD-fed male apoE−/− mice). Such effects of trehalose
were not associated with changes of plasma cholesterol, LDL, or HDL. Interestingly, while inefficient
in terms of inhibition of atherosclerosis, oral trehalose was able to attenuate hepatic steatosis even in
an aggressive model of the disease (HFD-fed apoE−/− mice). The anti-steatotic action of trehalose
in the liver was associated with the induction of autophagy. Yet, the exact molecular mechanisms
of both the anti-atherosclerotic action of trehalose and its inhibitory effect on liver steatosis require
further clarification.
So far, oral administration of trehalose has proved inefficient, which was referred to the presence
of the enzyme trehalase in the intestinal mucosa, kidney, liver, and blood of almost all mammals.
Trehalase rapidly hydrolyses trehalose to glucose, which could lead to a decrease of trehalose
bioavailability [32,33]. On the other hand, many studies have shown that orally administered
trehalose was present in the serum up to 4 h after intake and might exert therapeutic effects [15–18].
Moreover, some reports have indicated that trehalose is incompletely digested by trehalase in the
small intestine [34]. Likely, unabsorbed trehalose could be transformed to short-chain fatty acids
(SCFAs) by the intestinal microflora. Interestingly, it has been shown that SCFAs, such as acetate,
propionate, and butyrate, induce autophagy [35] and have anti-infla matory properties, which could
be protective in atherosclerosis [36]. However, we did not measure the level of trehalose and SCFAs
Int. J. Mol. Sci. 2019, 20, 1552 12 of 16
in the blood; therefore, whether the mechanism of action of trehalose is related to SCFAs requires
further investigations.
Taking into account all the above limitations, future pharmacological interventions based on the
anti-atherosclerotic action of this disaccharide should consider the combined use of trehalose with
trehalase inhibitors or degradation-resistant trehalose analogs.
4. Materials and Methods
4.1. Animal Experiments
All animal procedures were performed conforming the guidelines from Directive 2010/63/EU of
the European Parliament on the protection of animals used for scientific purposes and approved by
the Jagiellonian University Ethical Committee on Animal Experiments (no. 73/2011). Eighteen male
apoE–knockout mice and 18 female apoE–knockout (apoE−/−) mice on the C57BL/6J background
were purchased from Taconic (Ejby, Denmark). The animals were kept on 12 h dark/12 h light cycles
in air-conditioned rooms (22.5 ± 0.5 ◦C, 50 ± 5% humidity) with access to water ad libitum and diet.
The mice were put on a chow (CD) or a high-fat (HFD) diet made by Morawski (Kcynia, Poland) at
the age of 8 weeks for 16 weeks. The percentage composition of CD and HFD, showing differences in
the content of fat and cholesterol, is presented in Table 2. Four groups of animals were studied: male
apoE−/− mice on chow diet (n = 10), male apoE−/− mice on chow diet treated with trehalose (n = 8),
female apoE−/− mice on high-fat diet (n = 11), female apoE−/− mice on high-fat diet treated with
trehalose (n = 7). Trehalose (α-D-Glucopyranosyl-α-D-glucopyranoside, Sigma-Aldrich, Saint-Louis,
MO, USA) was mixed without heating with the same diet and administered to mice at a dose of 2.5 g
per kg of body weight per day. The dose of trehalose (2.5 g/kg of body weight per day) was chosen
according to the Food and Drug Administration (FDA) rules of animal-to-human equivalents and was
relevant to the average daily intake of trehalose estimated for the human population [37]. The animals
were injected with 1000 IU of fraxiparine i.p (Sanofi-Synthelabo, Paris, France) at the age of 6 months
and killed in a chamber filled with carbon dioxide. Next, the blood was collected, and aortas, hearts,
and livers were dissected.
Table 2. Percentage composition of a chow diet (CD) and a high-fat (HFD) diet.
Components Chow Diet (CD) High Fat Diet (HFD)
Fat 4% 15.2%
Cholesterol 0% 0.25%
Protein 17% 16.9%
Fiber 6.5% 5.4%
Ash 5.6% 5.3%
Others 66.9% 57%
4.2. Atherosclerosis Studies
Atherosclerosis development in apoE−/− mice was assessed using the en face method and
atherosclerosis evaluation at the aortic sinus, as described previously [38]. Briefly, 10 micrometer-thick
serial cryosections were stained with Meyer’s hematoxylin and oil red-O, picro-sirius red, and HE
(Sigma-Aldrich, Saint-Louis, MO, USA) and analyzed under an Olympus BX50 (Olympus, Tokyo,
Japan) microscope with the LSM Image Browser software (Zeiss, Jena, Germany).
4.3. Immunohistochemistry of Aortic Roots
For indirect immunohistochemistry, acetone-fixed sections of the ascending aorta were used. The
sections were preincubated overnight with 5% non-immunogenic goat serum with 2% fat-free milk
to block nonspecific binding of antibodies. Incubation with the primary antibody rat anti-mouse
CD68 (Serotec, Kidlington, UK) (dilution 1:800) was performed overnight at room temperature
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in wet chambers. Then, goat anti-rat IgG biotinylated antibody followed by DTAF-conjugated
streptavidin (Jackson IR, Cambridgeshire, UK) was applied to visualize the rat antibody. Sections
were examined using an epifluorescence Olympus BX50 microscope (Olympus, Tokyo, Japan)
equipped with appropriate filter cubes DTAF fluorescence. The images were registered with a
Camedia DP71 digital camera (Olympus, Tokyo, Japan). In each section, the total area occupied
by CD68-immunopositive macrophages was measured using the LSM Image Browser software (Zeiss,
Jena, Germany). Non-specific activity of gelatinases (mostly MMP-2 and MMP-9) in tissue sections was
demonstrated by in situ zymography. Unfixed sections were thawed and incubated for 2 h at 37 ◦C
in a dark humid chamber with a reaction buffer containing 50 mg/mL of FITC-labelled DQ-gelatin
(Invitrogen, Carlsbad, CA, USA). The sections were rinsed in PBS and fixed in 4% formaldehyde for
5 min, then mounted in glycerin/PBS. The fluorescence of gelatinase activity was observed under
a BX50 microscope (Olympus, Tokyo, Japan) equipped with a mercuric burner and an appropriate
filter set (U-MNIBA) and recorded with a DP71 camera (Olympus, Tokyo, Japan). The area displaying
fluorescence resulting from the enzymatic break-down of fluorescein isothiocyanate (FITC)-gelatin
represented local tissue gelatinase activity. Areas of MMP activity as well as intensities of fluorescence
(reflecting enzyme activity; pixel intensity/green channel: range 0–255) were measured in eight
sections from each sample, applying the LSM Image Browser software [38].
4.4. Histology of The Liver
The liver tissue samples were formalin fixed and embedded in paraffin, and 2 µm-thick paraffin
sections were stained with the HE method as described previously [21].
4.5. Biochemical Methods
Plasma was centrifuged at 1000× g at 4 ◦C for 10 min and stored at −80 ◦C. The levels of TG,
LDL, HDL, and total cholesterol were measured using commercial kits (Roche Molecular Biochemical,
Pleasanton, CA, USA). Moreover, the plasma levels of aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) were assayed by the Reflovet Plus equipment (Roche, Basel, Switzerland)
using commercial kits: Reflotron GOT, Reflotron GPT (Roche, Basel, Switzerland). TG levels in the
liver were assayed using the Triglyceride Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI,
USA), according to the manufacturer’s instructions.
4.6. Western Blot
Immunoblotting experiments were performed as previously described [39]. The following primary
antibodies were used: 1:1000 ANTI-Beclin 1 (Abcam, Cambridge, UK), 1:10000 ANTI-APG7 (Santa
Cruz, Dallas, TX, USA), 1:500 ANTI-LC3A/B (Abcam, Cambridge, UK), 1:5000 ANTI-β-actin (Sigma,
Saint-Louis, MO, USA). Images were recorded by the ImageQuant Las 500 (GE Healthcare, Chicago,
IL, USA) and analyzed using Image Lite Studio software (LI-COR, Lincoln, NE, USA).
4.7. Real-Time PCR
Real-time PCR experiments to determine the expression levels of genes related to autophagy
(ATG5, Beclin, LC3B) in the aorta of untreated and trehalose-treated apoE−/− mice on a CD as well as
an HFD were conducted as previously described [39]. Relative gene expression analysis with ACTB
(Bio Rad, Hercules, CA, USA) as reference gene was performed using the 7900HT fast real-rime PCR
System (Applied Biosystems, Foster City, CA, USA). The sequences of the designed primers were as
follows: 5′-CAC TGC TCT GTC TTG TGT AGG TTG-3′ (forward) and 5′-TCG TTG TGC CTT TAT
TAG TGC ATC-3′ (reverse) for LC3B; 5′-ACC ACA AGC AGC TCT GGA TGG GAC T-3′ (forward)
and 5′-GCC GCT CCG TCG TGG TCT GAT AT-3′ (reverse) for ATG5; 5′-GGG GTT TGC GGT TTT
TCT GGG AC-3′ (forward) and 5′-TCT CCA CGT CCA TCC ATC CTG TAC GGA AG -3′ (reverse)
for Beclin. The data were analyzed using the 2–∆∆Ct method by Data Assist v3.01 software (Applied
Biosystems, Foster City, CA, USA).
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4.8. Statistics
Results are presented as a mean + SEM. The equality of variance and the normality of the data were
checked and then the nonparametric Mann –Whitney U test or t-test were used for statistical analysis
of the data (Statistica 10, StatSoft, Krakow, Poland); p < 0.05 was considered as statistically significant.
Author Contributions: Conceptualization, R.O., J.J. and R.K.; Methodology, A.S., A.W., K.K., M.S., J.T.-Ż.; Formal
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